Hydroxychloroquine modulates elevated expression of S100 proteins in systemic lupus erythematosus

We investigated the effect of hydroxychloroquine (HCQ) on S100A8 and S100A9 serum levels in systemic lupus erythematosus (SLE) patients with low disease activity receiving immunosuppressants. SELENA-SLEDAI, Cutaneous Lupus Erythematous Disease Area and Severity Index (CLASI) and serum levels of complement factors, anti-dsDNA antibodies, and white blood cell, lymphocyte, and platelet counts were used to evaluate disease activity, cutaneous disease activity, and immunological activity, respectively. Serum S100A8 and S100A9 were measured at HCQ administration and after 3 or 6 months using ELISA. S100A8 and S100A9 serum levels were elevated at baseline and the magnitude of decrease from baseline at 3 and 6 months after HCQ administration was greater in patients with renal involvement than in those without (baseline: S100A8, p？=？0.034; S100A9, p？=？0.0084; decrease: S100A8, p？=？0.049; S100A9, p？=？0.023). S100 modulation was observed in patients with (n？=？17; S100A8, p？=？0.0011; S100A9, p？=？0.0002) and without renal involvement (n？=？20; S100A8, p？=？0.0056; S100A9, p？=？0.0012), and was more apparent in patients with improved CLASI activity scores (improved: S100A8, p？=？0.013; S100A9, p？=？0.0032; unimproved: S100A8, p？=？0.055; S100A9, p？=？0.055). No associations were observed for immunological biomarkers. HCQ may improve organ involvement in SLE by modulating S100 protein levels, especially in patients with renal or skin involvement